The Chief Executive Officer of Casella Waste Systems, Inc. (CWST), John Casella Unloaded 8,528 Shares; Biomarin Pharmaceutical (BMRN)’s Sentiment Is 1.13

Chief Executive Officer John Casella of Casella Waste Systems Inc, sold 8,528 of the firm shares having a total value of $207,539 U.S Dollars with an average of $24.3 stock price per share. It seems he is very active lately as in the last month, he quietly sold additional 19,571 shares of the company, worth $518,467 USD. John Casella owns 1.18% of the -company’s market cap or 494,794 shares.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $14.04 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

Investors sentiment decreased to 0.98 in Q3 2017. Its down 0.33, from 1.31 in 2017Q2. It is negative, as 22 investors sold Casella Waste Systems, Inc. shares while 38 reduced holdings. 18 funds opened positions while 41 raised stakes. 32.45 million shares or 1.47% more from 31.97 million shares in 2017Q2 were reported. Royal Bank & Trust Of Canada holds 0% or 428,154 shares. Mufg Americas Corp holds 557 shares or 0% of its portfolio. Price T Rowe Associates Inc Md holds 1.42 million shares. Moreover, Fenimore Asset Mgmt has 0.15% invested in Casella Waste Systems, Inc. (NASDAQ:CWST). Weber Alan W owns 35,000 shares for 0.31% of their portfolio. Manufacturers Life Insurance The holds 0% of its portfolio in Casella Waste Systems, Inc. (NASDAQ:CWST) for 30,991 shares. Legal And General Gru Public Limited holds 0% of its portfolio in Casella Waste Systems, Inc. (NASDAQ:CWST) for 11,228 shares. Sg Americas Secs Limited owns 6,568 shares. Pnc Svcs accumulated 4,349 shares. Globeflex Cap Ltd Partnership reported 0.15% of its portfolio in Casella Waste Systems, Inc. (NASDAQ:CWST). Commercial Bank Of New York Mellon Corp reported 406,237 shares stake. Portolan Cap Limited Liability Corp invested 3.57% of its portfolio in Casella Waste Systems, Inc. (NASDAQ:CWST). Van Eck Assocs Corporation reported 0% in Casella Waste Systems, Inc. (NASDAQ:CWST). Tiaa Cref Management Limited Liability Company owns 295,328 shares or 0% of their US portfolio. Driehaus Cap Management Ltd invested in 0.22% or 297,729 shares.

Among 8 analysts covering Casella Waste Systems Inc. (NASDAQ:CWST), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Casella Waste Systems Inc. has $22.0 highest and $7 lowest target. $13.75’s average target is -44.71% below currents $24.87 stock price. Casella Waste Systems Inc. had 17 analyst reports since August 21, 2015 according to SRatingsIntel. The stock of Casella Waste Systems, Inc. (NASDAQ:CWST) earned “Buy” rating by Zacks on Wednesday, August 19. Stifel Nicolaus maintained Casella Waste Systems, Inc. (NASDAQ:CWST) on Friday, November 3 with “Hold” rating. The rating was maintained by Wedbush on Monday, November 7 with “Neutral”. Stifel Nicolaus downgraded the stock to “Hold” rating in Wednesday, October 4 report. The stock has “Strong Buy” rating by Raymond James on Tuesday, January 26. The stock has “Hold” rating by Stifel Nicolaus on Thursday, January 4. Stifel Nicolaus maintained the shares of CWST in report on Monday, August 28 with “Buy” rating. The stock of Casella Waste Systems, Inc. (NASDAQ:CWST) has “Buy” rating given on Thursday, September 3 by Zacks. Stifel Nicolaus upgraded Casella Waste Systems, Inc. (NASDAQ:CWST) on Monday, May 9 to “Buy” rating. The stock of Casella Waste Systems, Inc. (NASDAQ:CWST) has “Equal-Weight” rating given on Friday, December 9 by First Analysis.

Since September 15, 2017, it had 0 insider buys, and 3 selling transactions for $2.96 million activity. $315,000 worth of Casella Waste Systems, Inc. (NASDAQ:CWST) was sold by CALLAHAN JAMES F JR on Wednesday, December 13. $564,638 worth of Casella Waste Systems, Inc. (NASDAQ:CWST) was sold by BURKE MICHAEL K on Friday, September 15. Another trade for 99,091 shares valued at $2.08 million was made by Johnson Edwin D on Tuesday, December 12.

Casella Waste Systems, Inc., together with its subsidiaries, operates as a vertically-integrated solid waste services firm in the northeastern United States. The company has market cap of $1.05 billion. The firm operates through Eastern Region, Western Region, Recycling, and Other divisions. It currently has negative earnings. It offers resource management services primarily in the areas of solid waste collection and disposal, transfer, recycling, and organics services to residential, commercial, municipal, and industrial customers.

The stock decreased 2.28% or $0.58 during the last trading session, reaching $24.87. About 666,370 shares traded or 219.20% up from the average. Casella Waste Systems, Inc. (NASDAQ:CWST) has risen 99.42% since March 2, 2017 and is uptrending. It has outperformed by 82.72% the S&P500.

Since January 1, 0001, it had 0 buys, and 10 sales for $9.95 million activity.

The stock increased 2.82% or $2.19 during the last trading session, reaching $79.86. About 1.68 million shares traded or 23.76% up from the average. BioMarin Pharmaceutical Inc. (BMRN) has risen 5.29% since March 2, 2017 and is uptrending. It has underperformed by 11.41% the S&P500.